Management of elderly patients with congestive heart failure--design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)

American Heart Journal
Hans Peter Brunner-La RoccaTIME-CHF-Investigators

Abstract

Little is known about the management of elderly patients with congestive heart failure (CHF) although they represent the majority of the CHF population. Therefore, the TIME-CHF study was set up (1) to evaluate the medical management of very old patients (> or = 75 years) with CHF compared with younger patients (60-74 years), (2) to compare an intensified with a standard treatment approach, and (3) to differentiate between systolic and diastolic dysfunction (ejection fraction < or = 45% vs > 45%). In a prospective single-blinded multicenter trial, 824 symptomatic patients, CHF hospitalization within the last year and elevated NT-BNP, are randomized to an intensified versus a standard medical therapy. Treatment strategies follow the published guidelines with the aim to reduce symptoms to NYHA class < or = II (standard) or, additionally, NT-BNP levels below twice the upper limit of normal (intensified). The primary end points are 18-month hospitalization-free survival and quality of life. By the end of 2004, 297 patients have been included, 147 randomized to intensified and 150 to standard therapy. Mean age in the older age group was 82 +/- 4 years (n = 174) and 69 +/- 4 years in the younger group (n = 123), respectively. Ejection...Continue Reading

References

Apr 1, 1990·Controlled Clinical Trials·W D Dupont, W D Plummer
Sep 19, 2000·Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology·R Latini, S Masson
Feb 24, 2001·Journal of Cardiovascular Pharmacology·Y OhtaY Aizawa
Jul 14, 2001·Journal of the American College of Cardiology·V VaccarinoH M Krumholz
Sep 15, 2001·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·E F LewisL W Stevenson
Dec 12, 2001·Neurology·G ZuccalàUNKNOWN GIFA-ONLUS Study Group [Grupo Italiano di Farmacoepidemiologia nell'Anzanio]
Feb 19, 2002·Age and Ageing·Ahmed H Abdelhafiz
Apr 5, 2002·The New England Journal of Medicine·Terri R FriedHeather Allore
May 30, 2002·European Journal of Heart Failure·Simon StewartJohn J J V McMurray
Aug 3, 2002·Archives of Internal Medicine·Asefeh HeiatHarlan M Krumholz
Jan 9, 2003·JAMA : the Journal of the American Medical Association·Margaret M RedfieldRichard J Rodeheffer
Jul 18, 2003·Lancet·Henry Krum, Richard E Gilbert
Mar 11, 2004·The American Journal of Geriatric Cardiology·Sunil T MathewGerard Aurigemma
Apr 12, 2005·The American Journal of Cardiology·James L JanuzziKent B Lewandrowski
May 20, 2005·European Heart Journal·Karl SwedbergUNKNOWN Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology

❮ Previous
Next ❯

Citations

Nov 1, 2008·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Patrick MüllerMichael Böhm
Mar 15, 2011·The American Journal of Bioethics : AJOB·Edward L Korn, Boris Freidlin
Nov 10, 2011·European Heart Journal·Hans-Peter Brunner-La RoccaUNKNOWN TIME-CHF Investigators
Aug 19, 2008·Cardiology in Review·Shafiq U Rehman, James L Januzzi
Feb 28, 2008·Current Opinion in Cardiology·Debra L Isaac
Nov 21, 2007·Drugs & Aging·Gregor LeibundgutHans-Peter Brunner-La Rocca
Oct 1, 2008·Biomarkers in Medicine·Roy S Gardner, Theresa A McDonagh
Oct 18, 2013·QJM : Monthly Journal of the Association of Physicians·T BurkardUNKNOWN Time-CHF Investigators
Dec 18, 2013·Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·J M P W U PeetersH P Brunner-La Rocca
Dec 1, 2007·Biomarkers in Medicine·Wayne L MillerAllan S Jaffe
Jan 1, 2009·Wiener klinische Wochenschrift·Micha Tobias MaederPeter Ammann
Sep 12, 2012·The International Journal of Cardiovascular Imaging·Beat A KaufmannHans-Peter Brunner-La Rocca
Dec 4, 2008·Heart Failure Reviews·J Paul RocchiccioliAnna F Dominiczak
Apr 21, 2009·Heart Failure Reviews·Kirkwood F AdamsChristopher M O'Connor
Dec 24, 2013·Journal of Cardiac Failure·Vanessa P M van EmpelHans-Peter Brunner-La Rocca
Aug 25, 2009·American Heart Journal·G Michael FelkerChristopher M O'Connor
Jul 28, 2009·Heart Failure Clinics·Guido BoerrigterJohn C Burnett
Jan 15, 2008·International Journal of Cardiology·Micha T MaederHans P Brunner-La Rocca
Feb 22, 2008·The American Journal of Cardiology·Richard W Troughton, A Mark Richards
Sep 29, 2007·Archives of Gerontology and Geriatrics·Joost H W RuttenAnton H van den Meiracker
Mar 28, 2007·Heart Failure Clinics·Richard W Troughton, A Mark Richards
Oct 17, 2015·European Journal of Heart Failure·S Sanders-van WijkUNKNOWN TIME-CHF investigators
May 20, 2015·International Journal of Cardiology·Beat A KaufmannUNKNOWN TIME-CHF investigators
Nov 15, 2008·European Journal of Heart Failure·Alison P ColettaJohn G F Cleland
Apr 28, 2007·European Journal of Heart Failure·Golyar KeyhanLouise Pilote
Sep 2, 2010·Journal of Internal Medicine·T SocratesC Mueller
Jul 10, 2012·European Journal of Heart Failure·Peter RickenbacherUNKNOWN TIME-CHF Investigators
Dec 14, 2011·The American Journal of Cardiology·Stefano MuzzarelliUNKNOWN TIME-CHF Investigators
Aug 10, 2010·American Heart Journal·Stefano MuzzarelliUNKNOWN TIME-CHF Investigators
Mar 27, 2015·European Journal of Heart Failure·Hans-Peter Brunner-La RoccaUNKNOWN TIME‐CHF investigators
Aug 16, 2016·JACC. Heart Failure·A Mark Richards
May 13, 2015·Journal of Telemedicine and Telecare·Carolina VaronSabine V Huffel

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.